Are Pediatric GLP-1 Prescriptions Moving Faster Than the Evidence?
Explore the risks, research gaps, and long-term safety questions surrounding GLP-1 weight-loss drugs prescribed to children and adolescents.
Are GLP-1 Medications Replacing Bariatric Surgery?
New research finds GLP-1 medications are replacing bariatric surgery for many young people with obesity, while access disparities remain a concern.
How Young Is Too Young for GLP-1 Meds?
Should children under 12 take GLP-1 weight-loss drugs? Learn the benefits, risks, expert opinions, and why doctors remain divided on early treatment.
Some Doctors Are Prescribing GLP-1 Weight-Loss Drugs to Children Under 12
Some physicians are prescribing GLP-1 weight-loss medications off-label for children under 12 with severe obesity.
Medicare Opens the Door to GLP-1 Weight-Loss Medications
The Medicare GLP-1 Bridge launches July 1, giving eligible seniors access to Wegovy and Zepbound for obesity treatment at $50 monthly.
Studies Suggest GLP-1 Medications May Help Slow Progression of Some Cancers
New research suggests GLP-1 medications may help slow the progression of certain cancers and reduce mortality risk, though more studies are needed.
GLP-1 Coverage Cuts by Medicaid
Some states are reconsidering Medicaid coverage for GLP-1 weight loss drugs amid rising costs. What does it mean for obesity treatment access?
Genetics May Shape the Future of GLP-1 Medications
Explore how genetics may influence the effectiveness of GLP-1 medications in children with obesity, and what personalized treatment means for the future.
The Rise of GLP-1 Medications in Pediatric Obesity: Breakthrough or Barrier?
Learn how GLP-1 medications are transforming childhood obesity treatment, including benefits, risks, and access challenges for families.
Family Values and Trust Shape Decisions About GLP-1 Meds for Kids
Caregivers’ trust, values, and food insecurity shape decisions about GLP-1 medications for children with obesity, highlighting need for shared decision-making.